Optimized Infliximab Induction Predicts Better Long-Term Clinical and Biomarker Outcomes Compared to Standard...

Area of Science:

• Pediatric Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory Bowel Disease (IBD) management in children requires effective induction strategies.
• Standard infliximab induction may not consistently achieve optimal therapeutic drug levels.
• Optimizing infliximab dosing could enhance treatment efficacy and long-term outcomes in pediatric IBD.

Purpose of the Study:

• To compare the efficacy of standard versus optimized infliximab induction dosing.
• To assess corticosteroid (CS)-free clinical remission at week 52.
• To evaluate the impact of post-induction infliximab trough levels on long-term outcomes in pediatric IBD patients.

Main Methods:

• Retrospective analysis of pediatric IBD patients (≤18 years) treated with infliximab.
• Comparison between a standard induction cohort (Glasgow) and an optimized induction cohort (Vancouver).
• Optimization included clinical assessment, biomarkers, and proactive infliximab trough level monitoring.

Main Results:

• Optimized induction resulted in significantly higher CS-free clinical remission at week 52 (83% vs. 52%, P < 0.001).
• Combined CS-free clinical and biomarker remission was also higher in the optimized group (83% vs. 40%, P < 0.001).
• Higher post-induction infliximab trough levels were associated with CS-free remission (3.6 mg/L vs. 2.0 mg/L, P = 0.04).

Conclusions:

• Standard infliximab induction is less effective for long-term outcomes in pediatric IBD.
• Optimized induction strategies improve post-induction infliximab trough levels.
• Optimized induction increases the likelihood of achieving long-term clinical remission in pediatric IBD.